TNDM — Tandem Diabetes Care Income Statement
0.000.00%
Last trade - 00:00
- $2.00bn
- $1.81bn
- $747.72m
- 62
- 22
- 87
- 58
C2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 362 | 499 | 703 | 801 | 748 |
Cost of Revenue | |||||
Gross Profit | 194 | 261 | 376 | 413 | 368 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 379 | 507 | 680 | 894 | 981 |
Operating Profit | -16.7 | -7.96 | 22.7 | -92.8 | -233 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -24.6 | -36.3 | 15.9 | -92.9 | -220 |
Provision for Income Taxes | |||||
Net Income After Taxes | -24.8 | -34.4 | 15.6 | -94.6 | -223 |
Net Income Before Extraordinary Items | |||||
Net Income | -24.8 | -34.4 | 15.6 | -94.6 | -223 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -24.8 | -34.4 | 15.6 | -94.6 | -223 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.423 | -0.564 | 0.242 | -1.42 | -3.31 |